Xevinapant is an investigational new drug that is being evaluated to treat squamous cell cancer.[1] By acting as a SMAC mimetic, it functions as an inhibitor of several members of the IAP protein family (including XIAP, c-IAP1, and c-IAP2).[2]
Clinical data | |
---|---|
Other names | AT 406; Debio-1143 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C32H43N5O4 |
Molar mass | 561.727 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ "Xevinapant - Merck & Co". AdisInsight. Springer Nature Switzerland AG.
- ^ Ferris RL, Harrington K, Schoenfeld JD, Tahara M, Esdar C, Salmio S, et al. (February 2023). "Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck". Cancer Treatment Reviews. 113: 102492. doi:10.1016/j.ctrv.2022.102492. PMC 11227656. PMID 36640618.